Roger Tung, Concert CEO
With a make-or-break PhIII readout looming, a struggling Concert offloads a 'portfolio' of drugs
A one-time high-flying biotech which once had big plans for its platform tech is jettisoning a “portfolio” of pipeline drugs as it hunkers down for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
